D. E. Shaw & Co., Inc. Axogen, Inc. Transaction History

D. E. Shaw & Co., Inc.

$122 Billion
Q4 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Axogen, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 488,306 shares of AXGN stock, worth $8.61 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

488,306

Previous 634,344 23.02%

Holding current value

$8.61 Million

Previous $8.89 Million 9.51%

% of portfolio

0.01%

Previous 0.01%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$12.47 - $17.19 $1.82 Million - $2.51 Million	-146,038 Reduced 23.02%	488,306 $8.05 Million
Q3 2024 Nov 14, 2024	BUY	$7.52 - $14.69 $193,707 - $378,399	25,759 Added 4.23%	634,344 $8.89 Million
Q2 2024 Aug 14, 2024	BUY	$5.67 - $8.06 $11,510 - $16,361	2,030 Added 0.33%	608,585 $4.41 Million
Q1 2024 May 15, 2024	SELL	$6.63 - $10.69 $29,390 - $47,388	-4,433 Reduced 0.73%	606,555 $4.89 Million
Q4 2023 Feb 14, 2024	BUY	$3.61 - $7.76 $128,310 - $275,813	35,543 Added 6.18%	610,988 $4.17 Million
Q3 2023 Nov 14, 2023	SELL	$4.68 - $9.26 $652,190 - $1.29 Million	-139,357 Reduced 19.5%	575,445 $2.88 Million
Q2 2023 Aug 14, 2023	BUY	$8.5 - $10.38 $345,219 - $421,573	40,614 Added 6.02%	714,802 $6.53 Million
Q1 2023 May 15, 2023	SELL	$7.53 - $10.95 $267,382 - $388,823	-35,509 Reduced 5.0%	674,188 $6.37 Million
Q4 2022 Feb 14, 2023	BUY	$9.44 - $13.09 $489,558 - $678,847	51,860 Added 7.88%	709,697 $7.08 Million
Q3 2022 Nov 14, 2022	SELL	$8.14 - $12.25 $639,502 - $962,396	-78,563 Reduced 10.67%	657,837 $7.84 Million
Q2 2022 Aug 15, 2022	SELL	$6.99 - $10.0 $503,217 - $719,910	-71,991 Reduced 8.91%	736,400 $6.03 Million
Q1 2022 May 16, 2022	BUY	$7.26 - $10.7 $132,727 - $195,617	18,282 Added 2.31%	808,391 $6.42 Million
Q4 2021 Feb 14, 2022	BUY	$8.8 - $16.0 $1.59 Million - $2.88 Million	180,185 Added 29.54%	790,109 $7.4 Million
Q3 2021 Nov 15, 2021	BUY	$15.23 - $21.72 $169,951 - $242,373	11,159 Added 1.86%	609,924 $9.64 Million
Q2 2021 Aug 16, 2021	SELL	$17.8 - $23.5 $246,832 - $325,874	-13,867 Reduced 2.26%	598,765 $12.9 Million
Q1 2021 May 17, 2021	SELL	$17.18 - $22.6 $757,878 - $996,976	-44,114 Reduced 6.72%	612,632 $12.4 Million
Q4 2020 Feb 16, 2021	SELL	$11.5 - $17.96 $1.15 Million - $1.79 Million	-99,593 Reduced 13.17%	656,746 $11.8 Million
Q3 2020 Nov 16, 2020	SELL	$10.62 - $13.12 $41,322 - $51,049	-3,891 Reduced 0.51%	756,339 $8.8 Million
Q2 2020 Aug 14, 2020	BUY	$7.35 - $10.81 $341,694 - $502,546	46,489 Added 6.51%	760,230 $7.03 Million
Q1 2020 May 15, 2020	SELL	$8.38 - $17.34 $1.63 Million - $3.36 Million	-193,981 Reduced 21.37%	713,741 $7.42 Million
Q4 2019 Feb 14, 2020	BUY	$11.18 - $18.6 $1.01 Million - $1.68 Million	90,406 Added 11.06%	907,722 $16.2 Million
Q3 2019 Nov 14, 2019	BUY	$12.09 - $20.46 $2.61 Million - $4.42 Million	216,198 Added 35.97%	817,316 $10.2 Million
Q2 2019 Aug 14, 2019	BUY	$18.5 - $25.47 $5.26 Million - $7.25 Million	284,479 Added 89.84%	601,118 $11.9 Million
Q1 2019 May 15, 2019	BUY	$14.62 - $22.13 $2.34 Million - $3.55 Million	160,318 Added 102.56%	316,639 $6.67 Million
Q4 2018 Feb 14, 2019	BUY	$17.09 - $38.25 $2.67 Million - $5.98 Million	156,321 New	156,321 $3.19 Million
Q3 2018 Nov 14, 2018	SELL	$34.05 - $55.9 $562,471 - $923,412	-16,519 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$36.15 - $52.5 $167,121 - $242,707	4,623 Added 38.86%	16,519 $830,000
Q1 2018 May 15, 2018	BUY	$24.4 - $40.25 $290,262 - $478,814	11,896 New	11,896 $434,000
Q4 2017 Feb 14, 2018	SELL	$18.5 - $28.6 $447,829 - $692,320	-24,207 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$14.65 - $19.35 $354,632 - $468,405	24,207	24,207 $468,000

Others Institutions Holding AXGN

# of Institutions

179

Shares Held

36.2M

Call Options Held

82.6K

Put Options Held

1.1K

View Full List

About Axogen, Inc.

Ticker AXGN
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 42,283,700
Market Cap $745M
Description
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...

More about AXGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account